Avrobio -based biotech start-up Avrobio has raised $60m in a series B funding round col-led by Cormorant Asset Management and Surveyor Capital . Massachusetts has developed a gene therapy for Fabry disease, a lysosomal storage disorder which allows fatty deposits to build up in the body. Clinical trials last autumn saw patients' enzyme levels match those without the disease, with no side-effects after 2016 of treatment. The latest funding, which followed a $25m series A in last autumn , will be used to begin a phase two trial of the gene therapy AVR -RD-01.
Massachusetts-based biotech start-up Avrobio has raised $60m in a series B funding round col-led by Cormorant Asset Management and Surveyor Capital. Avrobio has developed a gene therapy for Fabry disease, a lysosomal storage disorder which allows fatty deposits to build up in the body. Clinical trials last autumn saw patients' enzyme levels match those without the disease, with no side-effects after six months of treatment. The latest funding, which followed a $25m series A in 2016, will be used to begin a phase 2 trial of the gene therapy AVR-RD-01.